| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 22nd December 2020 | Jay Venkatesan | 181,024 | Other acquisition or disposition | $0.00 | |
| 22nd December 2020 | Jay Venkatesan | 993,801 | Other acquisition or disposition | $0.00 | |
| 14th October 2020 | Bali Muralidhar | 200,000 | Open or private purchase | $15.00 | $3,000,000.00 |
| 14th October 2020 | Bali Muralidhar | 1,592,518 | Conversion of derivative | $0.00 | |
| 6th July 2020 | Jay Venkatesan | 9,310 | Exercise of derivative | $0.65 | $6,051.50 |
| 6th July 2020 | Jay Venkatesan | 12,930 | Exercise of derivative | $1.03 | $13,317.90 |
| 12th June 2020 | Llc Aurasense | 10,195 | Open or private sale | $2.83 | $28,851.85 |
| 12th June 2020 | Chad A. Mirkin | 10,195 | Open or private sale | $2.83 | $28,851.85 |
| 20th May 2020 | Chad A. Mirkin | 49,649 | Exercise of derivative | $0.65 | $32,271.85 |
| 13th March 2020 | David R Walt | 291,066 | Open or private purchase | $1.21 | $352,859.31 |
Exicure
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Exicure, Inc. engages in the provision of clinical stage biotechnology company. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
Ticker: XCUR
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
SEC Central Index Key (CIK): 1698530
Employees:
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $17 M (0%)
Assets, Current: $89 M (-20%)
Property, Plant and Equipment, Net: $4 M (0%)
Other Assets, Noncurrent: $2 M (0%)
Assets: $96 M (-16%)
Long-term Debt, Current Maturities: $0 (-100%)
Accounts Payable, Current: $2 M (-15%)
Accrued Liabilities, Current: $2 M (0%)
Liabilities, Current: $14 M (-53%)
Liabilities: $14 M (-58%)
Common Stock, Value, Issued: $9 Th (0%)
Common Stock, Shares, Issued: $87 M (0%)
Retained Earnings (Accumulated Deficit): $84 M (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $338 Th (1151%)
Stockholders' Equity (Parent): $82 M (0%)
Liabilities and Equity: $96 M (-16%)
Revenue: $5 M (-65%)
Research and Development: $7 M (-46%)
General and Administrative Expenses: $2 M (-53%)
Operating Income/Loss: $4 M (13%)
Other Income, net: $79 Th (-88%)
News
Top Stocks To Buy In March
8th March 2021
Top Stocks To Buy In March
7th March 2021